重症成人推注升压药的安全性与有效性
该单中心回顾性队列研究在1273张床位的学术医学中心开展(2018年6月至2020年7月),评估手术室外重症患者推注升压药(PDP)的实践模式、疗效与安全性。主要结局为收缩压升高25%,去氧肾上腺素组达标率55.9%(1140例),肾上腺素组达标率71.8%(102例)。去氧肾上腺素中位剂量400 μg(IQR 200-888 μg),肾上腺素中位剂量50 μg(IQR 20-100 μg)。不良反应少见,最常见为高血压:去氧肾上腺素组6.6%、肾上腺素组13.4%。作者结论认为PDP去氧肾上腺素与肾上腺素治疗急性低血压期安全有效。
要点
- 手术室外重症患者推注去氧肾上腺素中位剂量400 μg(IQR 200-888 μg),收缩压升高25%达标率55.9%(1140例)。
- 推注肾上腺素中位剂量50 μg(IQR 20-100 μg),收缩压升高25%达标率71.8%(102例)。
- 推注后不良反应少见,高血压最常见:去氧肾上腺素组6.6%、肾上腺素组13.4%。
- 作者结论认为PDP去氧肾上腺素与肾上腺素治疗急性低血压期安全有效。
适用人群与场景
- 大型学术医学中心手术室外重症成人患者,接受推注升压药(PDP)治疗急性低血压期。
诊断标准与关键阈值
- 疗效定义为收缩压升高25%。
处置流程与药物剂量
- 去氧肾上腺素推注中位剂量400 μg(IQR 200-888 μg)。
- 肾上腺素推注中位剂量50 μg(IQR 20-100 μg)。
研究设计与关键结果
- 单中心回顾性队列研究,2018年6月至2020年7月,1273张床位学术医学中心,最终纳入1727例患者。
- 主要结局(收缩压升高25%)达标:肾上腺素组102例(71.8%),去氧肾上腺素组1140例(55.9%)。
- 去氧肾上腺素中位剂量400 μg(IQR 200-888 μg),肾上腺素中位剂量50 μg(IQR 20-100 μg)。
- 不良反应少见,最常见为高血压:去氧肾上腺素组6.6%,肾上腺素组13.4%;安全性结局还包括心动过缓与心动过速。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为PDP去氧肾上腺素与肾上腺素治疗急性低血压期安全有效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate practice patterns, efficacy, and safety of push dose pressors (PDP) in critically ill patients outside of the operating room (OR) at a large academic medical center.
MATERIALS AND METHODS: This was a single-center, retrospective cohort study (June 2018 to July 2020) conducted at a 1273-bed academic medical center. The primary outcome was efficacy, defined as a 25% increase in systolic blood pressure, and the cohort was analyzed according to PDP response (i.e. responders versus non-responders). A logistic regression model was used to assess predictors of response to PDPs. Safety outcomes included the incidence of hypertension, bradycardia, and tachycardia.
RESULTS: 1727 patients were included in the final analysis. The median doses of phenylephrine and epinephrine administered were 400 μg (IQR 200-888 μg) and 50 μg (IQR 20-100 μg). The primary outcome was achieved in 102 (71.8%) patients in the epinephrine group and 1140 (55.9%) of patients in the phenylephrine group. Adverse effects after PDP receipt were minimal, with the most common being hypertension in 6.6% and 13.4% of the phenylephrine and epinephrine groups respectively.
CONCLUSIONS: This study demonstrates that PDP phenylephrine and epinephrine are safe and efficacious in treating the acute hypotensive period.
参考来源
- Singer S, Pope H, Fuller BM, et al. The safety and efficacy of push dose vasopressors in critically ill adults. Am J Emerg Med. 2022. PMID: 36108346. doi:10.1016/j.ajem.2022.08.055
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。